This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
You do not have access to the full text of this article, the first page of the PDF of this article appears above.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't.
January 2019
Volume 7, Issue 1
Volume 7, Issue 1
A Sampling of Highlights from the Literature
Jump to section
- Article
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
- A cancer cell program promotes T-cell exclusion and resistance to checkpoint blockade
- TGF-β–associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
- Defining T-cell states associated with response to checkpoint immunotherapy in melanoma
- IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
- High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy
- Info & Metrics
Advertisement